Outcomes in patients with mixed cardiogenic and vasoplegic shock
Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock: a French Multicenter Cohort
This registry will try to describe outcomes and risk factors in adults admitted with cardiogenic shock who also have inappropriate vasodilation (mixed cardiogenic‑vasoplegic shock).
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens, Somme) |
| Trial ID | NCT07354568 on ClinicalTrials.gov |
What this trial studies
This retrospective multicenter observational registry collects routine clinical, laboratory, and invasive hemodynamic data from adults admitted to ICUs for cardiogenic shock with or without vasoplegia. The primary aim is to describe mortality and organ failure rates, and secondary analyses will identify determinants of adverse outcomes including vasopressor requirements and use of mechanical circulatory support such as VA‑ECMO. Inclusion requires adults (≥18) with cardiogenic shock at least SCAI stage C and available vasopressor and outcome data, while non‑eligible shock etiologies and pregnant patients are excluded. Data are contributed by participating French university hospitals (Amiens, Dijon, Rouen) and analyzed retrospectively to characterize the epidemiology and prognosis of the mixed phenotype.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) admitted to the ICU with cardiogenic shock at SCAI stage C or higher who have documented vasopressor dosing and outcome data and do not oppose use of their data.
Not a fit: Patients with excluded non‑cardiogenic shock causes (for example anaphylaxis, massive hemorrhage, major trauma, severe pancreatitis, fulminant hepatic failure, or neurogenic shock), pregnant women, those under legal protection, or those missing key vasopressor or outcome data are unlikely to benefit from the registry's findings.
Why it matters
Potential benefit: If successful, the registry could help clinicians better predict which patients are at highest risk and inform decisions about vasopressors and mechanical support.
How similar studies have performed: Other observational registries have characterized cardiogenic shock outcomes and experience with VA‑ECMO and vasopressors, but focusing specifically on the mixed cardiogenic‑vasoplegic phenotype is relatively novel and less well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (\>18 years old) * Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C * No opposition to data use Exclusion Criteria: * Missing key data, particularly regarding vasopressor doses and outcomes. * Pregnant women * Non-eligible shock etiologies, including but not limited to: * Anaphylactic shock, * Isolated hemorrhagic shock, * Severe burns or major trauma, * Severe acute pancreatitis, * Fulminant hepatic failure, * Neurogenic shock. * Adult under legal protection (guardianship, curatorship, or judicial protection).
Where this trial is running
Amiens, Somme
- CHU Amiens Picardie — Amiens, Somme, France (Recruiting)
Study contacts
- Study coordinator: Christophe Beyls, MD, PhD
- Email: beyls.christophe@chu-amiens.fr
- Phone: + 33 322087866
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.